BNTX Stock Analysis: BioNTech SE | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 23.312m USD | 12M Return: -17.6% | US09075V1026 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 77.2M
Qual. Beats: 0
Rev. Trend: -58.3%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 6.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
BioNTech SE (NASDAQ: BNTX) is a Mainz, Germany-based biotechnology company founded in 2008 that develops and commercializes immunotherapies, primarily leveraging its mRNA technology platform. The company gained global prominence with BNT162, its mRNA vaccine targeting SARS-CoV-2, and has since built out a broad clinical pipeline spanning oncology and infectious diseases.
The oncology portfolio is the largest component, with multiple candidates in Phase II and Phase III trials across lung, breast, colorectal, ovarian, pancreatic, and other cancers. Lead late-stage assets include Gotistobart (non-small cell lung cancer), Pumitamig (small cell lung cancer, triple-negative breast cancer, and other solid tumors), Trastuzumab pamirtecan (metastatic breast cancer), BNT113 (HPV-related head and neck cancer), and Autogene cevumeran (colorectal cancer).
Beyond oncology, BioNTech is advancing infectious disease vaccines in earlier-stage trials targeting mpox (BNT166), tuberculosis (BNT164), malaria (BNT165), and combination SARS-CoV-2/influenza candidates. Listed on NASDAQ since its October 2019 IPO, the company operates within the GICS Health Care / Biotechnology sub-industry and runs a platform-based business model in which its mRNA technology is applied across multiple therapeutic areas rather than focused on a single indication.
- COVID vaccine revenue declines sharply as demand normalizes
- Phase III oncology readouts approach for lead mRNA candidates
- Large cash reserves deployed to fund R&D and strategic acquisitions
| Net Income: -1.71b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 12.50 > 1.0 |
| NWC/Revenue: 504.4% < 20% (prev 489.1%; Δ 15.31% < -1%) |
| CFO/TA 0.04 > 3% & CFO 736.8m > Net Income -1.71b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.85 > 1.5 & < 3 |
| Outstanding Shares: last quarter (253.3m) vs 12m ago 4.85% < -2% |
| Gross Margin: 64.28% > 18% (prev 79.76%; Δ -15.48% > 0.5%) |
| Asset Turnover: 12.60% > 50% (prev 13.30%; Δ -0.70% > 0%) |
| Interest Coverage Ratio: -80.25 > 6 (EBIT TTM -1.52b / Interest Expense TTM 18.9m) |
| A: 0.66 (Total Current Assets 15.3b - Total Current Liabilities 1.95b) / Total Assets 20.3b |
| B: 0.82 (Retained Earnings 16.6b / Total Assets 20.3b) |
| C: -0.07 (EBIT TTM -1.52b / Avg Total Assets 21.0b) |
| D: 6.87 (Book Value of Equity 17.8b / Total Liabilities 2.58b) |
| Altman-Z'' = 13.69 = AAA |
| DSRI: 0.18 (Receivables 245.1m/1.45b, Revenue 2.65b/2.88b) |
| GMI: 1.24 (GM 79.76% / 64.28%) |
| AQI: 0.91 (AQ_t 0.19 / AQ_t-1 0.21) |
| SGI: 0.92 (Revenue 2.65b / 2.88b) |
| TATA: -0.12 (NI -1.71b - CFO 736.8m) / TA 20.3b) |
| Beneish M = -3.60 (Cap -4..+1) = AAA |
As of August 19, 2026, the stock is trading at USD 92.75 with a total of 921,566 shares traded. Over the past week, the price has changed by -0.05%, over one month by +0.64%, over three months by +4.39% and over the past year by -17.59%.
Current recommended Stop Loss: 87.30 (which is 5.9% or 2.2 ATR below the current price).
BioNTech SE has received a consensus analysts rating of 4.38. Therefore, it is recommended to buy BNTX.
- StrongBuy: 13
- Buy: 3
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 120.3 | 29.7% |
Market Cap EUR = 20.1b (23.3b USD * 0.8638 USD.EUR)
P/E Forward = 7.0373
P/S = 8.7969
P/B = 1.1358
P/EG = 0.046
Revenue TTM = 2.65b EUR
EBIT TTM = -1.52b EUR
EBITDA TTM = -838.3m EUR
Long Term Debt = 258.9m EUR (from longTermDebt, last quarter)
Short Term Debt = 57.2m EUR (from shortTermDebt, last quarter)
Debt = 541.4m EUR (from shortLongTermDebtTotal, last quarter) + Leases 225.4m
Net Debt = -9.20b EUR (calculated: Debt 541.4m - CCE 9.74b)
Enterprise Value = 10.9b EUR (20.1b + Debt 541.4m - CCE 9.74b)
Interest Coverage Ratio = -80.25 (Ebit TTM -1.52b / Interest Expense TTM 18.9m)
EV/FCF = 21.11x (Enterprise Value 10.9b / FCF TTM 518.3m)
FCF Yield = 4.74% (FCF TTM 518.3m / Enterprise Value 10.9b)
FCF Margin = 19.60% (FCF TTM 518.3m / Revenue TTM 2.65b)
Net Margin = -64.49% (Net Income TTM -1.71b / Revenue TTM 2.65b)
Gross Margin = 64.28% ((Revenue TTM 2.65b - Cost of Revenue TTM 944.8m) / Revenue TTM)
Gross Margin QoQ = -152.0% (prev -63.17%)
Tobins Q-Ratio = 0.54 (Enterprise Value 10.9b / Total Assets 20.3b)
Interest Expense / Debt = 3.50% (Interest Expense 18.9m / Debt 541.4m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -1.20b (EBIT -1.52b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.85 (Total Current Assets 15.3b / Total Current Liabilities 1.95b)
Debt / Equity = 0.03 (Debt 541.4m / totalStockholderEquity, last quarter 17.8b)
Debt / EBITDA = 10.97 (negative EBITDA) (Net Debt -9.20b / EBITDA -838.3m)
Debt / FCF = -17.74 (Net Debt -9.20b / FCF TTM 518.3m)
Total Stockholder Equity = 18.5b (last 4 quarters mean from totalStockholderEquity)
RoA = -8.13% (Net Income -1.71b / Total Assets 20.3b)
RoE = -9.20% (Net Income TTM -1.71b / Total Stockholder Equity 18.5b)
RoCE = -8.08% (EBIT -1.52b / Capital Employed (Equity 18.5b + L.T.Debt 258.9m))
RoIC = -6.56% (negative operating profit) (NOPAT -1.20b / Invested Capital 18.3b)
WACC = 8.66% (E(20.1b)/V(20.7b) * Re(8.82%) + D(541.4m)/V(20.7b) * Rd(3.50%) * (1-Tc(0.21)))
Discount Rate = 8.82% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 73.98 | Cagr: 2.33%
[DCF] Terminal Value 74.35% ; FCFF base≈518.3m ; Y1≈520.5m ; Y5≈551.3m
[DCF] Fair Price = 69.02 (EV 8.14b - Net Debt -9.20b = Equity 17.3b / Shares 251.2m; r=8.66% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.42 | # QB: 0
Revenue Correlation: -58.30 | Revenue CAGR: -15.37% | SUE: -0.19 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.76 | Chg30d=+15.18% | Revisions=-25% | Analysts=5
EPS current Year (2026-12-31): EPS=-4.97 | Chg30d=-7.84% | Revisions=+12% | GrowthEPS=-934.5% | GrowthRev=-36.2%
EPS next Year (2027-12-31): EPS=-4.86 | Chg30d=-9.86% | Revisions=+12% | GrowthEPS=+2.1% | GrowthRev=+1.9%
[Analyst] Revisions Ratio: +7% (up=6, down=5)